Select your Market
-
- Algeria
- Angola
- Benin
- Botswana
- Burkina Faso
- Burundi
- Cameroon
- Cape Verde
- Central African Republic
- Chad
- Comoros
- Congo
- Congo Democratic Republic
- Djibouti
- Egypt
- Equatorial Guinea
- Eritrea
- Ethiopia
- Gabon
- Gambia
- Ghana
- Guinea
- Guinea-Bissau
- Ivory Coast
- Kenya
- Lesotho
- Liberia
- Libya
- Madagascar
- Malawi
- Mauritania
- Mauritius
- Morocco
- Mozambique
- Namibia
- Niger
- Nigeria
- Reunion Islands
- Rwanda
- Saint Helena
- São Tomé and Príncipe
- Senegal
- Seychelles
- Sierra Leone
- Somalia
- South Africa
- Sudan
- Swaziland
- Tanzania
- Togo
- Tunisia
- Uganda
- Zambia
- Zimbabwe
-
- Albania
- Austria
- Baltic Region
- Belarus
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Netherlands
- North Macedonia
- Norway
- Poland
- Portugal
- Romania
- Russian Federation
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Türkiye
- Ukraine
- United Kingdom
Collaboration in Healthcare - Strategic Focus & Partnerships
Our innovations in specialty care enable us to deliver the targeted medicines and novel, patient-friendly drug delivery systems that make a difference to patients, physicians and caregivers around the world.

The Healthcare business of Merck KGaA, Darmstadt, Germany, operates as EMD Serono in the U.S. and Canada.
-
Matthias Muellenbeck
Head of Global Business Development & Alliance Management
Building Alliances for patient-centric Solutions
For us, partnering is a key element in delivering meaningful therapies to patients with unmet medical needs. We support our business by translating our Specialty Innovator ambition into a differentiated, high-value pipeline that complements our internal R&D capabilities with the best external innovation.
In this regard, we seek opportunities that strengthen our focus on targeted specialty and rare diseases and combine compelling science and validated biology with attractive commercial potential. Our ambition is to identify differentiated assets and technologies where we can leverage our strengths and create meaningful value for patients.
We are consciously agnostic about where innovation originates, how we access it and across modalities, while maintaining a focused approach that currently does not actively target cell and gene therapies. Rather than being driven by the source of an opportunity, we focus on its quality, strategic fit, and potential to contribute to sustainable growth. Through creative deal structures and alliances on a global and regional level, we bring the most promising external innovation into our portfolio.
-
Gregor Fachinger
Head of Global Business Development Oncology & Hematology
Oncology & Hematology
As an active player in Oncology, Rare Tumors and Hematology, we are seeking and evaluating pre-clinical and early- to mid-stage clinical opportunities to strengthen our pipeline. We strive to access targeted opportunities addressing high medical need with relevant fit to our specialized therapeutics solid tumor indications, which include, but are not limited to:
- Focussed GI-tumor indications (e.g. CRC, gastric, PDAC)
- Niches in lung cancer, SCCHN
- Rare solid tumors, e.g. sarcomas, CNS tumors and related entities (e.g. desmoid tumors)
In the hematology space, we are focusing on:
- Hemato-oncology
- Non-tumor hematology
- Vascular and bleeding disorders, incl. vascular malformations
-
Marta Helena Lesko
Head of Global Business Development Immunology
Immunology
Our focus is
the development of best-in-disease therapeutics in diseases, with particularinterest in:
- Rheumatology
- Dermatology
- Ommune-driven hematologic disorders
- Rare immune-driven disorders
- Inflammatory gastrointestinal disorders
- (Auto-)immune-driven kidney diseases
- Pulmonary disorders – inflammatory and other
non-immune rare respiratory disorders
-
Jan Moeller
Head of Global Business Development CM&E and Fertility
Fertility & CM&E
Fertility & Pediatric Endocrinology
As a world leader in fertility treatment, we develop and provide innovative products, devices, and support services to assist infertile couples at every stage of the fertility treatment cycle, from follicular development to early pregnancy.
We actively search for and evaluate preclinical and clinical assets and technologies that align with our commitment to innovation and offer clear differentiation potential.
Our search scope includes novel therapeutics and technologies for:
- Female infertility
- Male infertility
- Diminished ovarian reserve & premature ovarian insufficiency
In addition, we are interested in therapeutics in reproductive health adjacencies, such as placenta biology (e.g. preeclampsia) and the inflammatory/cytokine axis (e.g. endometriosis), and are also exploring opportunities in Pediatric Endocrinology, Bone-Mineral Disorders and (rare) Musculoskeletal Disorders.
Cardiometabolic & Adult Endocrinology
Our purpose is to bring better health to every single cardiology, metabolic and endocrine patient, helping them to live their life to its full potential. Currently we address chronic diseases such as diabetes, hypertension, growth hormone disorders or hypothyroidism, in view of their impact on health and society. Through our leading and affordable portfolio, ‘beyond the pill’ solutions and partnerships, we are helping to improve awareness, diagnosis, treatment and adherence of these diseases.
Every day, some 70 million patients across the globe use our trusted medicines like Glucophage® and Glucovance® (Diabetes); Concor® (Cardiovascular); Euthyrox® (Thyroids) or Saizen® (Growth hormone deficiency). Our long-lasting and successful presence in Emerging Markets is based on strong local commercial and medical infrastructure as well as continued investment in our established brands.
Moving forward we aim to fuel additional growth via innovative specialty medicines in orphan disease areas:
- Precision cardiology
- Endocrine axis disroders
- Inborn errors of metabolism & Lysosomal Storage Disorders
- Rare biliary or hepatic disorders, metabolic kidney diseases
Regional emerging market opportunities for close-to-commercial stage opportunities that synergize with our existing portfolio (descr
ibed above) are also of interest.
-
Roby Kanichay
VP, Head of Technologies, Global Health & Externalizations
Technologies
To support our pre-clinical discovery and development efforts across our therapeutic areas, we search for and evaluate novel technologies in following areas:
Technologies that transfer differentiation, speed and efficiency to our “armed antibody” platforms, incl.
- Next-gen novel payloads beyond tubulin- & Topoisomerase inhibitors
- AOC constructs
- Novel targeting technologies
- Novel linker technologies
Novel delivery technologies allowing for larger therapeutic index and delivery of novel agents (e.g. oligonucleotide moieties) to target organs.
Differentiated degrader technologies allowing for e.g. tissue specificity or tackling difficult to drug targets.
Innovative technologies for binder generation in the antibody and degrader context.Access to large scale multi-omics datasets, HOR and RWD as well as tools for the improvement of clinical development e.g., clinical patient stratification, site selection and clinical trial success predictions.
Externalization Network
We are regularly reviewing our development candidate portfolio and are actively seeking partnerships for assets that we have strategically deprioritized. Such assets are typically in the late stage-preclinical / early-stage clinical development stage.
We are open to discuss partnering proposals with pharma and biotech organizations to license such assets but are also open to build new companies around such assets with VC/PE investors.
-
Markus Kropf
Head of Global Alliance Management
Alliance Management
- Maximizing the value of the alliance for both partners, and reducing the risk of failure
- Resolving issues in advance in the best interest of the projects
- Providing a lead alliance governance structure
- Monitoring whether the legal framework of current alliances still reflects the initial objectives in light of environmental changes
- New Opportunities: Identifying new opportunities with current partners